Focus Partners Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.69M Buy
24,596
+4,754
+24% +$1.17M 0.01% 935
2026
Q2
$4.78M Buy
19,842
+4,925
+33% +$1.08M ﹤0.01% 980
2026
Q1
$2.84M Buy
14,917
+5,150
+53% +$900K ﹤0.01% 1162
2025
Q4
$1.66M Buy
9,767
+5,224
+115% +$801K ﹤0.01% 1408
2025
Q3
$599K Sell
4,543
-812
-15% -$97.4K ﹤0.01% 1538
2025
Q2
$568K Buy
5,355
+732
+16% +$79.5K ﹤0.01% 1377
2025
Q1
$574K Buy
4,623
+145
+3% +$18.9K ﹤0.01% 1286
2024
Q4
$551K Buy
+4,478
New +$528K ﹤0.01% 1279
2024
Q3
– Sell
-4,220
Closed -$450K – 1645
2024
Q2
$450K Buy
4,220
+183
+5% +$20.1K ﹤0.01% 969
2024
Q1
$445K Buy
+4,037
New +$494K ﹤0.01% 745

Other funds holding JAZZ

Focus Partners Wealth's JAZZ Position: Q3 2026 in Review

Focus Partners Wealth increased its Jazz Pharmaceuticals (JAZZ) stake by 24% in Q3 2026, buying an estimated $1.17M and bringing the position to 24,596 shares worth $5.69M. The position accounts for 0.01% of the portfolio, ranked #935.

Focus Partners Wealth first reported a position in JAZZ in Q1 2024 and has held it in 10 quarters since. 559 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Focus Partners Wealth held 24,596 shares of Jazz Pharmaceuticals worth $5.69M as of Q3 2026.
  • Focus Partners Wealth bought 4,754 Jazz Pharmaceuticals shares in Q3 2026, an estimated $1.17M.
  • Jazz Pharmaceuticals made up 0.01% of Focus Partners Wealth's portfolio in Q3 2026, its #935 holding.
  • Focus Partners Wealth first reported a position in Jazz Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 559 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Focus Partners Wealth's 13F filing for Q3 2026, filed 12 Nov 2026.